Literature DB >> 22633082

Pregnancy-associated inflammatory markers are elevated in pregnant women with systemic lupus erythematosus.

S Björkander1, K Bremme, J-O Persson, R F van Vollenhoven, E Sverremark-Ekström, U Holmlund.   

Abstract

During normal pregnancy a dampening in T cell-mediated immunity is compensated by an increased pro-inflammatory activity. Likewise, the autoimmune disease systemic lupus erythematosus (SLE) is associated with inflammatory activity and pregnancy complications occur frequently in women with SLE. The aim of this study was to elucidate how SLE influences the chemokine and cytokine balance during and after pregnancy. Blood samples were taken from pregnant women with or without SLE at second and third trimester and 8-12 weeks after pregnancy. Cytokines (interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-17A, TNF, IFN-γ and IFN-α), chemokines (CXCL8/IL-8, CXCL9/MIG, CXCL10/IP-10, CCL2/MCP-1, CCL5/RANTES and CCL17/TARC), soluble IL-6 receptor (sIL-6R) and soluble glycoprotein 130 (gp130) were measured in serum using cytometric bead array (CBA) or enzyme-linked immunosorbent assay (ELISA). Women with SLE had increased serum concentrations of CXCL8/IL-8, CXCL9/MIG, CXCL10/IP-10 and IL-10 compared to controls both during and after pregnancy. Further, when dividing the patients based on disease activity, the women with active disease had the highest levels. Importantly, women with SLE seemed to respond to pregnancy in a similar way as controls, since the changes of cytokines and chemokines over the course of pregnancy were similar but with overall higher levels in the patient group. In conclusion, changes in pro- and anti-inflammatory serum components during pregnancy in women with SLE, occurring on top of already more pro-inflammatory levels, might increase their risk for pregnancy complications and flares. How their children are affected by this heightened inflammatory milieu during pregnancy needs further investigation.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22633082     DOI: 10.1016/j.cyto.2012.04.046

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

1.  Predictors of maternal and fetal complications in SLE patients: a prospective study.

Authors:  Elisabetta Borella; Andrea Lojacono; Mariele Gatto; Laura Andreoli; Marco Taglietti; Luca Iaccarino; Edoardo Casiglia; Leonardo Punzi; Angela Tincani; Andrea Doria
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  Risk factors of systemic lupus erythematosus flares during pregnancy.

Authors:  Luis J Jara; Gabriela Medina; Pilar Cruz-Dominguez; Carmen Navarro; Olga Vera-Lastra; Miguel A Saavedra
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

3.  Pregnancy-associated systemic lupus erythematosus.

Authors:  Rahime Nida Ergin
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-07

4.  In vivo immune signatures of healthy human pregnancy: Inherently inflammatory or anti-inflammatory?

Authors:  Caroline Graham; Rishma Chooniedass; William P Stefura; Allan B Becker; Malcolm R Sears; Stuart E Turvey; Piush J Mandhane; Padmaja Subbarao; Kent T HayGlass
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

5.  Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis.

Authors:  Pongpratch Puapatanakul; Sonchai Chansritrakul; Paweena Susantitaphong; Thornthun Ueaphongsukkit; Somchai Eiam-Ong; Kearkiat Praditpornsilpa; Wonngarm Kittanamongkolchai; Yingyos Avihingsanon
Journal:  Int J Mol Sci       Date:  2019-10-08       Impact factor: 5.923

Review 6.  Understanding and Managing Pregnancy in Patients with Lupus.

Authors:  Guilherme Ramires de Jesus; Claudia Mendoza-Pinto; Nilson Ramires de Jesus; Flávia Cunha Dos Santos; Evandro Mendes Klumb; Mario García Carrasco; Roger Abramino Levy
Journal:  Autoimmune Dis       Date:  2015-07-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.